Koyfin Home > Directory > Health Care > Antares Pharma > Gross Margin

Antares Pharma Gross Margin Chart (ATRS)

Antares Pharma annual/quarterly Gross Margin from 2000 to 2018. Gross margin is a company's total sales revenue minus its cost of goods sold (COGS), divided by total sales revenue, expressed as a percentage. The higher the percentage, the more the company retains on each dollar of sales, to service its other costs and debt obligations.
  • Antares Pharma Gross Margin for the quarter ending December 12, 2018 was $49m a 11.06% increase of 5m year over year
  • Antares Pharma Gross Margin for the last 12 months ending December 12, 2018 was $51m a 5.12% increase of 3m year over year
  • Antares Pharma Annual Gross Margin for 2018 was $51m a 2.94% increase of 2m from 2017
  • Antares Pharma Annual Gross Margin for 2017 was $50m a 9.67% increase of 5m from 2016
  • Antares Pharma Annual Gross Margin for 2016 was $45m a -28.04% decrease of -13m from 2015
Other Margins & Efficiency Metrics:
  • Antares Pharma EBITDA Margin for the quarter ending December 12, 2018 was $-27m a -45.38% increase of 12m year over year
  • Antares Pharma Return on Capital % for the quarter ending December 12, 2018 was -25.15 a -0.12% increase of 0.03 year over year
  • Antares Pharma Return on Equity % for the quarter ending December 12, 2018 was 77.43 a 203.55% increase of 157.61 year over year
View Chart On Koyfin

Quarterly ATRS Gross Margin Data

12/2018$49m
09/2018$59m
06/2018$51m
03/2018$43m
12/2017$49m
09/2017$43m
06/2017$58m
03/2017$48m
12/2016$53m
09/2016$40m

Annual ATRS Gross Margin Data

2018$51m
2017$50m
2016$45m
2015$57m
2014$58m
2013$55m
2012$58m
2011$59m
2010$67m
2009$50m